India’s leading multinational pharmaceutical company Dr Reddy's Laboratories on Thursday said it has launched Fluphenazine Hydrochloride tablets, used for management of manifestations of psychotic disorders, in the United State market. The product is a therapeutic equivalent generic version of Prolixin tablets approved by the US Food and Drug Administration (USFDA).

In a regulatory filing, Dr Reddy's Laboratories announced the launch of Fluphenazine Hydrochloride tablets in the US.

Quoting IQVIA Health data, Dr Reddy's said Prolixin brand and generic had US sales of approximately USD 134 million for the most recent 12 months ending in December 2020.

Dr Reddy's Fluphenazine Hydrochloride tablets, USP, are available in 1 mg, 2.5 mg, 5 mg, and 10 mg tablets in 100 bottle count sizes.

Reacting to the development, Shares of Dr Reddy's Laboratories' share price touched an intraday high at Rs 4663.85 on the National Stock Exchange on Thursday.  In comparison, the BSE Sensex traded at  51485 and the NSE Nifty stood at 15165.

Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company located in Hyderabad, Telangana, India. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. The company has over 190 medications, 60 active pharmaceutical ingredients (APIs) for drug manufacture, diagnostic kits, critical care, and biotechnology products.

Stock in Focus: NALCO share buyback opens on February 25

Paytm Money opens stock market trading in F&O segment

Union Cabinet clears trade pact with Mauritius